Starpharma Pty Ltd: Clinical Trials

9 trials sponsored by Starpharma Pty Ltd, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed. 4 Phase 3, 3 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4
Phase 13Completed 3
Phase 23Completed 3

Follow Starpharma Pty Ltd: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel - Bacterial Vaginosis
Phase 3CompletedStarpharma Pty Ltd5862014-10-132019-07-22
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel - Bacterial Vaginosis
Phase 3CompletedStarpharma Pty Ltd6372014-10-032018-06-25
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
1% SPL7013 Gel, Placebo - Bacterial Vaginosis
Phase 3CompletedStarpharma Pty Ltd2512012-04-172019-07-17
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
1% SPL7013 Gel, Placebo - Bacterial Vaginosis
Phase 3CompletedStarpharma Pty Ltd2502012-03-282019-07-17
Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)
1% SPL7013 Gel, 3% SPL7013 Gel, placebo gel - Recurrent Bacterial Vaginosis (BV)
Phase 2CompletedStarpharma Pty Ltd2052011-08-012013-11-20
Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)
0.5% SPL7013 Gel, 1.0% SPL7013 Gel, 3.0% SPL7013 Gel - Bacterial Vaginosis
Phase 2CompletedStarpharma Pty Ltd1322010-08-012019-06-06
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
3% SPL7013 Gel (VivaGel) - HIV Infections, HSV-2 Genital Herpes
Phase 1 / Phase 2CompletedStarpharma Pty Ltd122008-08-012018-10-30
Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women
3% SPL7013 Gel (VivaGel), Placebo Gel, HEC Placebo Gel - Healthy
Phase 1CompletedStarpharma Pty Ltd612007-07-012010-06-24
SPL7013 Gel - Male Tolerance Study
3% w/w SPL7013 Gel (VivaGel™) - Human Immunodeficiency Virus (HIV)
Phase 1CompletedStarpharma Pty Ltd362006-08-012008-01-16

Conditions studied

Vaginosis, Bacterial (6)  ·  Acquired Immunodeficiency Syndrome (1)  ·  HIV Infections (1)  ·  Recurrence (1)

Interventions

astodrimer (7)  ·  Metronidazole (2)

Countries

United States (4)  ·  Australia (2)  ·  Puerto Rico (2)  ·  Bulgaria (1)  ·  Canada (1)  ·  Czechia (1)  ·  Hungary (1)  ·  Ukraine (1)  ·  United Kingdom (1)

Top investigators

Jeremy Paull, PhD (3)  ·  Jeremy Paull, PhD. (2)  ·  Anne Macek, MD (1)  ·  Ian McGowan, MD, PhD (1)  ·  Marcus Chen, MD, PhD (1)

Results publications

PMID 21505316